Information Links
Previous Issues Volume 8, Issue 2 - 2023
First Report of M-My Mind Study
Humberto Martínez-Cordero1,2,3,*, Luis Antonio Salazar2, Jair Figueroa2, Maria Isabel Arbeláez2, Alejandro Rico Mendoza3,4, Alexandra Porras Ramírez3,4,5, Henry Idrobo2, Viviana Olaya2, Kenny Gálvez2, Sergio Cancelado2, Juan Manuel Herrera2, Leonardo Bautista Toloza2, Jessica Zapata Malagón3, Lorena Cubillos Osorio3, Isabella Novoa-Caicedo3, On Behalf of GRIMMCO (Colombian Multiple Myeloma Research Group) and GRHEMUB (El Bosque University Hematology Group)
1Princess Margaret Cancer Centre UHN, University of Toronto, Toronto, Canada
2Colombian Multiple Myeloma Research Group, Colombia
3El Bosque University Hematology Group, Colombia
4Community Medicine and Collective Health Group, El Bosque University, Colombia
5Coordination of Epidemiology and Research, Los Cobos Medical Center, Colombia
*Corresponding author: Dr. Humberto Martínez-Cordero, MD MSc, Hematology Clinical and Research Fellowship in Multiple Myeloma, Princess Margaret Cancer Center, University of Toronto, Canada; E-mails: [email protected], [email protected].
Received Date: March 15, 2023
Published Date: April 25, 2023
Citation: Martínez-Cordero H, et al. (2023). First Report of M-My Mind Study. Mathews J Cancer Sci. 8(2):41.
Copyrights: Martínez-Cordero H, et al. © (2023).
ABSTRACT
Multiple myeloma (MM) is a heterogeneous and incurable disease considered the second most common hematologic malignancy globally. The incidence, prevalence, and mortality worldwide are well-known thanks to the data reported by the International Agency for Research on Cancer (IARC) and by the Global Cancer Observatory GLOBOCAN. Our objective was to estimate the incidence, prevalence, and mortality of MM in Colombia in this work. The total population diagnosed with multiple myeloma (ICD Code 10 C900) during the 2008-2018 period was used, which was included in the RIPS (Registro Individual de Prestación de Servicios) in Colombia.
The standardized incidence and prevalence rates for Colombia in 2018 were 1.79 (CI 1.76-1.81) and 8.97 x 100,000 inhabitants/year (CI8.94-8.99), respectively. The age-standardized mortality rate for Colombia was 1.39 x 100,000 inhabitants (1.36-1.41) (adjusted with the population of the United States). The prevalence was higher than that reported by other sources and is comparable with those of the whole world, North America, and Spain. MM must be one of the cancers in which epidemiology must prioritize and organize health cancer care due to the ageing population.
Keywords: Multiple Myeloma, Colombia, Incidence, Prevalence, Epidemology.
